type of reaction becomes possible as soon as the chemical complexity of the reactants is increased beyond that of the simplest case. In the case of ethyl iodide and chlorine, the competing reaction is an E2 elimination, in which Cl -pulls a hydrogen atom away from the methyl group to form hydrogen chloride (HCl), and the resulting rearrangement of electrons in the organic reactant leads to the formation of a double bond between the two carbon atoms, eventually yielding ethene (CH 2 =CH 2 ) as I -is ejected. As in the S N 2 mechanism, the process takes place in a single step, with simultaneous bond formation and breakage.
Carrascosa et al. went on to study several similar reactions under different conditions, to investigate competition between the S N 2 and E2 mechanisms in detail. Their method of direct visualization allowed them to identify at least two subtypes of the E2 mechanism, depending on whether the reactant halogen ion approached the organic reactant from the same side as the departing halogen ion, or the opposite side.
In common with any gas-phase method, the authors' approach does not provide direct information about how solvent molecules affect the reaction mechanism -in practice, organic reactions are almost always performed in solution. However, if experiments such as those of Carrascosa et al. were combined with studies of the same reactions in solution, the results might provide a new way to separate the solvent effects from reactant effects.
There will also be a limit -yet to be established -to the complexity of reactions that can be studied using the authors' technique. This is partly because interpreting the data becomes more difficult as molecular size increases, but also because preparing large molecules in the gas phase is a considerable challenge. For reactions that are too complex for a full study to be performed, useful insights might still be gained by looking at simplified model systems. Nevertheless, the new work paves the way for an exciting array of mechanistic studies. For example, this approach could be used to study how reaction mechanisms alter in response to steric effects, which occur when bulky groups of atoms block access to certain parts of a molecule, or to investigate whether reactions that are thought to occur through several steps actually do so. ■ 2 demonstrate that lymphangiogenesis in and around skin cancers called melanomas and their nearest lymph nodes is not necessarily required for initial metastasis. Instead, the primary tumour can induce aberrant lymphangiogenesis in distant lymph nodes and organs, paving the way for cancer cells to follow.
The authors engineered several different mouse models of melanoma such that expression of the gene Vegfr3 -which encodes a protein that mediates lymphangiogenesis 3 -drove production of a bioluminescent protein called luciferase. This allowed the researchers to track lymphangiogenesis at the cellular and organismal level in the mice, revealing four distinct patterns of lymphangiogenesis relative to metastatic progression.
Notably, vessel formation around the tumour occurred independently of lymphangiogenesis at distant sites, leading Olmeda and colleagues to conclude that lymphangiogenesis around the primary tumour does not determine whether tumour cells colonize distant lymph nodes and organs. Furthermore, intra-tumoral expression of the
METASTASIS

Lymphatic detours for cancer
The growth factor MIDKINE, which is secreted by skin tumours called melanomas, stimulates the formation of lymphatic vessels at distant lymph nodes and organ sites, paving the way for metastatic cancer spread. See Letter p.676 protein VEGFC, which binds to and activates VEGFR3, did not correlate with the formation of distant metastases. This indicates that VEGFR3-mediated lymphangiogenesis at distant sites is independent of VEGFC production by primary tumours. Previous work [4] [5] [6] has demonstrated that tumours induce the formation of premetastatic niches -sites that can sustain the growth of tumour cells -in distant organs before tumour-cell colonization. When primary melanomas are removed, relapse might occur in these niches 7 . Olmeda et al. showed that small primary tumours induced systemic luciferase expression in the lymph nodes, lungs, spleen and liver. Is lymphangiogenesis a marker of pre-metastatic niches? Tumour removal in the authors' mice was followed by relapse at these sites. Furthermore, removal of the primary tumour led to a marked reduction in luciferase expression in pre-metastatic regions, which reactivated suddenly before relapse. These data indicate that activation of distal lymphangiogenesis, driven by tumour cells, is supportive of pre-metastatic niche formation (Fig. 1) .
Olmeda and colleagues next focused on identifying tumour-secreted factors other than VEGFC that might promote distant lymphangiogenesis and metastasis 8 , and alighted on the soluble protein MIDKINE (MDK). This growth factor has been shown 9 to mediate metastatic progression by promoting inflammation, blood-vessel growth and cell proliferation in other cancers, but a role in lymphangio genesis has not previously been reported.
The authors demonstrated that MDK overexpression converted a non-lymphangiogenic melanoma with low metastatic potential into a potent driver of systemic lymphangiogenesis, resulting in disseminated disease.
By contrast, MDK downregulation in an aggressive melanoma led to drastic inhibition of lymphangiogenesis, and reduced the number of metastases.
The researchers showed that MDK stimulates lymphangiogenesis by activating the protein mTOR in lymphatic endothelial cells (which line lymphatic vessels), inducing their proliferation. Finally, they provided evidence that MDK enhances tumour-cell adhesion to lymphatic endothelial cells, indicating that the protein might promote tumour colonization at sites of lymphangiogenesis, in addition to its role in stimulating vessel formation. Together, the authors' data reveal a mechanism by which the primary tumour, through secretion of MDK, induces lymphangiogenesis, and this, in turn, promotes pre-metastatic niche formation through as-yet-unknown mechanisms.
Olmeda and colleagues' study raises several questions. For instance, the authors' model might lead to the assumption that MDK (either in soluble form or in vesicles called exosomes) travels away from the primary tumour, through tissues, to the nearest lymphatic vessel, from where it can circulate to distant lymphatic endothelial cells. However, it is also possible that MDK circulates through blood vessels -in which case, what effect might it have on vascular endothelial cells? Furthermore, what is the receptor protein on lymphatic endothelial cells that mediates the lymphangiogenic effects of MDK?
It is likely that other tumour-secreted factors cooperate with MDK to promote lymphangiogenesis, and it will be interesting to identify these factors and determine their mechanisms of action. In addition, although the authors have shown that Vegfr3 expression is a marker of pre-metastatic niches, its precise role in tumour-driven lymphangiogenesis and meta stasis remains to be defined, as do potential roles for other members of the VEGFR protein family. Together, these analyses should provide a broader picture of how tumour-driven lymphangiogenesis is regulated.
Because the researchers found that local and distant lymphatic vessels formed independently of one another, the molecular profiles and functions of lymphatic endothelial cells might differ depending on which tissue they reside in -akin to the situation in vascular endothelial cells 10 . Lymphatic endothelial cells in different tissues might, therefore, react differently to tumour-derived factors, suggesting that any future therapies that target lymphangio genesis need to be tailored to each organ.
As our understanding of the early steps of metastasis expands, so does the realization that we must better predict metastatic risk and better detect pre-metastatic events if we are to halt the spread of cancer. Olmeda et al. provide much-needed insights in this vein. In a final set of experiments, they showed that high MDK levels in lymph nodes were associated with poor prognosis in people with melanoma, even if there were no tumour cells in the lymph nodes. This observation, together with the study's other findings, provides a rationale for targeting lymphangiogenesis and its molecular drivers (such as mTOR) as soon as primary tumours are detected.
MDK and lymphangiogenesis, respectively, could be ideal molecular and functional biomarkers of metastatic risk, if they can be measured sensitively enough -something that future studies could address. Real-time lymphatic-vessel imaging using near-infrared probes 11, 12 is already being used in the clinic; the development of more-sensitive probes could enable valuable routine monitoring of early-stage and post-treatment cancer. In this way, Olmeda 2 have uncovered a pathway by which skin cancers called melanomas can undergo metastatic spread to distant lymph nodes and organs. Contrary to what many researchers thought, the process does not involve formation of lymphatic vessels (lymphangiogenesis) in and around the primary tumour. Instead, the growth-factor protein MIDKINE (MDK) is secreted by the tumour as a soluble factor and in vesicles called exosomes. It circulates to pre-metastatic lymph nodes and organs, where metastasis will arise in the future (whether it circulates in the blood, lymph or both is unclear). The protein promotes lymphangiogenesis at these sites. The presence of lymphangiogenic vessels helps to prepare the sites for the arrival of cancer cells. 
